Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLYMPIA-5: odronextamab + lenalidomide versus rituximab + lenalidomide in relapsed/refractory follicular lymphoma or marginal zone lymphoma
2022-503092-28-00Phase 3Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial in follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL) comparing Odronextamab + lenalidomide with Rituximab + lenalidomide (2 arms). Primary endpoints: Incidence of dose limiting toxicities for odronextamab in combination with lenalidomide, Incidence of treatment emergent adverse events for odronextamab in combination with lenalidomide and 2 more. Planned start Sep 2023; status: authorised.
02
Drugs
odronextamablenalidomiderituximab
03
Conditions
follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2022-503092-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503092-28-00.